21:29 , Jun 21, 2019 |  BioCentury  |  Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders' topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren't eligible for biologics. Frazier Healthcare launched the company in 2016...
22:37 , May 29, 2019 |  BC Extra  |  Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
19:48 , May 3, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
21:31 , Apr 1, 2019 |  BC Extra  |  Company News

Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...
19:33 , Mar 1, 2019 |  BC Week In Review  |  Company News

Bausch wins $195M bid to acquire bankrupt Synergy's assets

Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) won a $195 million bid to acquire assets of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) in a court-supervised bankruptcy auction. Synergy markets gastrointestinal drug Trulance plecanatide. Trulance is an uroguanylin analog...
00:04 , Feb 16, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg NeoGenomics Inc. (NASDAQ:NEO) 2/19 Pre $0.05 $0.05 0% Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) 2/20 Pre $0.84 $0.98 -14% Genmab A/S...
19:52 , Jan 17, 2019 |  BioCentury  |  Regulation

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...